- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07339722
Eine Studie zu LY4515100 bei gesunden Teilnehmern
Eine Phase-1-Studie, randomisiert, verblindet für Prüfarzt und Teilnehmer, placebokontrolliert, mit Einzel- und Mehrfach-Dosis-Eskalation zur Charakterisierung der Sicherheit, Verträglichkeit und Pharmakokinetik von LY4515100 bei gesunden Teilnehmern
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: LY4515100 via SAD
- Arzneimittel: LY4515100 via MAD
- Arzneimittel: LY4515100
- Arzneimittel: Itraconazole
- Arzneimittel: Metformin
- Arzneimittel: Caffeine
- Arzneimittel: Digoxin
- Arzneimittel: Iohexol
- Arzneimittel: Rosuvastatin
- Arzneimittel: Midazolam
- Arzneimittel: Midazolam
- Arzneimittel: Levonorgestrel
- Arzneimittel: Ethinyl Estradiol
- Arzneimittel: Placebo
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-Mail: LillyTrials@Lilly.com
Studieren Sie die Kontaktsicherung
- Name: Physicians interested in becoming principal investigators please contact
- E-Mail: clinical_inquiry_hub@lilly.com
Studienorte
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75247
- Rekrutierung
- Fortrea Clinical Research Unit
-
Hauptermittler:
- Gene Voskuhl
-
Kontakt:
- Telefonnummer: 866-429-3700
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53704
- Rekrutierung
- Fortrea Clinical Research Unit
-
Hauptermittler:
- Kimberly Cruz
-
Kontakt:
- Telefonnummer: 866-429-3700
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
-
Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
-
Individuals not of childbearing potential (INOCBP) may participate in this trial.
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- must be 18 to 45 years of age (inclusive).
- have a BMI within the range of 18.5 to 30 kg/m².
- may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion Criteria:
-
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
-
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
-
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
-
Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
-
Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
-
increases the risks associated with participating in the study
-
may confound ECG data analysis
-
Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
-
Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
-
Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
-
Show evidence of
-
Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
-
hepatitis C and/or positive hepatitis C antibody
-
hepatitis B and/or positive hepatitis B surface antigen.
-
Have liver disease.
-
Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
-
Part C Only:
- Have history of neuropathy of any cause.
- Have impaired hearing or a history of hearing problems.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
- Participants with any known history of thyroid disease
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
- Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
- Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
- Have undiagnosed abnormal uterine bleeding.
- Have any history of breast, uterine or ovarian cancer.
- Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
- Have contraindications for the use of levonorgestrel/ethinyl estradiol.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: LY4515100 of Part A (SAD)
Single-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 of Part B (MAD)
Multiple-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 and Itraconazole of Part C
LY4515100 and Itraconazole will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Metformin of Part C
LY4515100 and Metformin will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Transporter Substrates or Renal Marker of Part C
LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
given orally given orally given orally given IV given orally |
|
Experimental: LY4515100 and Midazolam of Part C
LY4515100 will be given orally. Midazolam will be given orally and IV. |
given orally given orally given IV |
|
Experimental: LY4515100 and Combined Oral Contraceptive of Part C
LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally |
given orally given orally given orally |
|
Placebo-Komparator: Placebo Part A
Placebo will be given orally |
given orally |
|
Placebo-Komparator: Placebo Part B
Placebo will be given orally |
given orally |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
Zeitfenster: Day 1 up to Day 30
|
SAEs of LY4515100 |
Day 1 up to Day 30
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Zeitfenster: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Zeitfenster: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
Zeitfenster: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
Zeitfenster: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
Zeitfenster: Day 1 through Day 11
|
PK: AUC of LY4515100 |
Day 1 through Day 11
|
|
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
Zeitfenster: Day 1 through Day 11
|
PK: Cmax of LY4515100 |
Day 1 through Day 11
|
|
PK: Time of maximum observed drug concentration (tmax) of LY4515100
Zeitfenster: Day 1 through Day 11
|
PK: tmax of LY4515100 |
Day 1 through Day 11
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Azolen
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenhydrate
- Carboxylsäuren
- Alkaloide
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glykoside
- Amides
- Purinonen
- Purines
- Pyrimidine
- Steroide
- Fusions-Ring-Verbindungen
- Benzolderivate
- Kohlenwasserstoffe, halogeniert
- Benzazepines
- Östradiol -Kongenere
- Gonadale Steroidhormone
- Gonadalhormone
- Biguanides
- Guanidine
- Amidines
- Säuren, carbocyclisch
- Sulfonamide
- Sulfone
- Benzoates
- Benzodiazepine
- Triazoles
- Fluorobenzene
- Kohlenwasserstoffe, fluoriert
- Piperazines
- Norpregnenes
- Norpregnanes
- Norsteroide
- Xanthine
- Triiodobenzoesäuren
- Iodbenzoates
- Digitalis Glycoside
- Cardenolides
- Herzglykoside
- Cardanolides
- Norpregnatrienes
- Östrogene Steroide, alkyliert
- Norgestrel
- Rosuvastatin Calcium
- Midazolam
- Digoxin
- Metformin
- Koffein
- Itraconazol
- Levonorgestrel
- Ethinylestradiol
- Iohexol
Andere Studien-ID-Nummern
- 27789
- J6V-MC-OIAB (Andere Kennung: Eli Lilly and Company)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .